A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis
Journal of Scleroderma and Related Disorders · 2025-10 · 10 (3) · 182-188
DOI: 10.1177/23971983251342697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 22.05.2025. Verfasst von Seher Sener und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Rheumatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
The use of Janus kinase inhibitors is increasing in systemic sclerosis, a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation. In this review, we aimed to examine the studies in the literature reporting on patients with systemic sclerosis treated with Janus kinase inhibitors.
Methods
We performed a search on MEDLINE and Scopus for articles involving patients with systemic sclerosis treated with Janus kinase inhibitors from the inception of these databases through 1 August 2024.
Results
Our literature search revealed 18 articles describing 87 systemic sclerosis patients treated with Janus kinase inhibitors. The median (min-max) age of these patients was 48.5 (13–78) years (F/M = 4.9). The most commonly used Janus kinase inhibitors in systemic sclerosis were tofacitinib (82.8%), followed by baricitinib (13.8%). Janus kinase inhibitors were most commonly used to treat the combination of interstitial lung disease and skin involvement (44.9%), and the combination of gastrointestinal system and skin involvement (38.8%). Improvement rates with Janus kinase inhibitors were 87.5%, and 5.9% of patients on Janus kinase inhibitors relapsed. Adverse events were observed in 50% of systemic sclerosis patients treated with Janus kinase inhibitors. Various infections (21.1%) were the most common adverse event reported following Janus kinase inhibitor use.
Conclusion
Although Janus kinase inhibitors seem to be very effective, especially in patients with systemic sclerosis who have resistant/progressive skin disease, some side effects should not be ignored. Therefore, controlled clinical trials in larger populations are needed on Janus kinase inhibitors use in systemic sclerosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Rheumatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Ankara Etlik State Research and Training Hospital, Ankara, Turkey.
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
ORCID-Profile: Seher Sener
Zitieren
APA
Sener, S., Sener, Y. Z., Batu, E. D., Sari, A., & Akdogan, A. (2025). A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders, 10(3), 182-188. https://doi.org/10.1177/23971983251342697
Vancouver
Sener S, Sener YZ, Batu ED, Sari A, Akdogan A. A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders. 2025;10(3):182-188. doi:10.1177/23971983251342697
BibTeX
@article{Sener2025,
author = {Sener, Seher and Sener, Yusuf Ziya and Batu, Ezgi Deniz and Sari, Alper and Akdogan, Ali},
title = {A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis},
journal = {Journal of Scleroderma and Related Disorders},
year = {2025},
volume = {10},
number = {3},
pages = {182--188},
doi = {10.1177/23971983251342697}
}
EUVIMED